PURPOSE: Magnetic resonance imaging (MRI) in patients with Cardiovascular Implantable Electronic Devices (CIED) has not been approved by the Food and Drug Administration. Recent data suggests MRI as a relative rather than absolute contraindication in CIED patients. Recently, the American Heart Association has recommended defibrillation threshold testing (DFTT) in implantable cardioverter defibrillator (ICD) patients undergoing MRI. We evaluated the feasibility and safety of a protocol for MRI in CIED patients, incorporating the new recommendations on DFTT. METHODS: Consecutive patients with CIED undergoing MRI were included. The protocol consisted of continuous monitoring during imaging, device interrogation pre- and post-MRI, reprogramming of the pacemaker to an asynchronous mode in pacemaker-dependent (PMD) patients and a non-tracking/sensing mode for non-PMD patients. All tachyarrhythmia therapies were disabled. Devices were interrogated for lead impedance, battery life, pacing, and sensing thresholds. All patients with ICD underwent DFTT/defibrillator safety margin testing (DSMT) post-MRI. RESULTS: A total of 92 MRI's at 1.5 Tesla were performed in 38 patients. A total of 13 PMD patients, ten ICD patients, four cardiac resynchronization therapy with defibrillator (CRT-D) patients, and 11 non-PMD patients were scanned from four major manufacturers. No device circuitry damage, programming alterations, inappropriate shocks, failure to pace, or changes in sensing, pacing, or defibrillator thresholds were found on single or multiple MRI sessions. CONCLUSIONS: Our protocol for MRI in CIED patients appears safe, feasible, and reproducible. This is irrespective of the type of CIED, pacemaker dependancy or multiple 24-h scanning sessions. Our protocol addresses early detection of potential complications and establishes a response system for potential device-related complications. Our observation suggests that routine DFTT/DSMT post-MRI may not be necessary.
PURPOSE: Magnetic resonance imaging (MRI) in patients with Cardiovascular Implantable Electronic Devices (CIED) has not been approved by the Food and Drug Administration. Recent data suggests MRI as a relative rather than absolute contraindication in CIED patients. Recently, the American Heart Association has recommended defibrillation threshold testing (DFTT) in implantable cardioverter defibrillator (ICD) patients undergoing MRI. We evaluated the feasibility and safety of a protocol for MRI in CIED patients, incorporating the new recommendations on DFTT. METHODS: Consecutive patients with CIED undergoing MRI were included. The protocol consisted of continuous monitoring during imaging, device interrogation pre- and post-MRI, reprogramming of the pacemaker to an asynchronous mode in pacemaker-dependent (PMD) patients and a non-tracking/sensing mode for non-PMDpatients. All tachyarrhythmia therapies were disabled. Devices were interrogated for lead impedance, battery life, pacing, and sensing thresholds. All patients with ICD underwent DFTT/defibrillator safety margin testing (DSMT) post-MRI. RESULTS: A total of 92 MRI's at 1.5 Tesla were performed in 38 patients. A total of 13 PMDpatients, ten ICDpatients, four cardiac resynchronization therapy with defibrillator (CRT-D) patients, and 11 non-PMDpatients were scanned from four major manufacturers. No device circuitry damage, programming alterations, inappropriate shocks, failure to pace, or changes in sensing, pacing, or defibrillator thresholds were found on single or multiple MRI sessions. CONCLUSIONS: Our protocol for MRI in CIED patients appears safe, feasible, and reproducible. This is irrespective of the type of CIED, pacemaker dependancy or multiple 24-h scanning sessions. Our protocol addresses early detection of potential complications and establishes a response system for potential device-related complications. Our observation suggests that routine DFTT/DSMT post-MRI may not be necessary.
Authors: J Rod Gimbel; Shane M Bailey; Patrick J Tchou; Paul M Ruggieri; Bruce L Wilkoff Journal: Pacing Clin Electrophysiol Date: 2005-10 Impact factor: 1.976
Authors: Claas P Naehle; Katharina Strach; Daniel Thomas; Carsten Meyer; Markus Linhart; Sascha Bitaraf; Harold Litt; Jörg Otto Schwab; Hans Schild; Torsten Sommer Journal: J Am Coll Cardiol Date: 2009-08-04 Impact factor: 24.094
Authors: Pierpaolo Lupo; Riccardo Cappato; Giovanni Di Leo; Francesco Secchi; Giacomo D E Papini; Sara Foresti; Hussam Ali; Guido M G De Ambroggi; Antonio Sorgente; Gianluca Epicoco; Paola M Cannaò; Francesco Sardanelli Journal: Eur Radiol Date: 2018-01-09 Impact factor: 5.315
Authors: Saman Nazarian; Rozann Hansford; Amir A Rahsepar; Valeria Weltin; Diana McVeigh; Esra Gucuk Ipek; Alan Kwan; Ronald D Berger; Hugh Calkins; Albert C Lardo; Michael A Kraut; Ihab R Kamel; Stefan L Zimmerman; Henry R Halperin Journal: N Engl J Med Date: 2017-12-28 Impact factor: 91.245
Authors: Saman Nazarian; Rozann Hansford; Ariel Roguin; Dorith Goldsher; Menekhem M Zviman; Albert C Lardo; Brian S Caffo; Kevin D Frick; Michael A Kraut; Ihab R Kamel; Hugh Calkins; Ronald D Berger; David A Bluemke; Henry R Halperin Journal: Ann Intern Med Date: 2011-10-04 Impact factor: 25.391